Product details
Background：Lacutamab is a humanized monoclonal antibody targeting KIR3DL2 that enhances the antitumor activity of natural killer cells (NK cells) and T cells and reduces tumor immune escape by blocking KIR3DL2 interaction with HLA ligands. KIR3DL2 expression is restricted in normal tissues, but is expressed in approximately 65% of patients with cutaneous t-cell lymphoma (CTCL) , especially in patients with Sézary syndrome, where the expression rate is up to 90% , about 50% are expressed in patients with mycosis fungoides and peripheral t-cell lymphoma. Its research background focuses on the regulation of immune cell activity by targeting KIR3DL2 receptor, which provides a new treatment strategy for refractory lymphomas such as CTCL. At present, a number of clinical trials continue to verify its safety and effectiveness.
